Compare SpaceX (SPCX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SpaceX vs TransMedics Group Inc — how do they compare? SpaceX trades at $148.84 (market cap $1.76T), while TransMedics Group Inc trades at $87.13 (market cap $3.10B). The key difference: SpaceX is far larger — about 567.7× TransMedics Group Inc's market cap, and SpaceX is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SPCX | TMDX | |
|---|---|---|
Market Cap | $1.76T | $3.10B |
Sector | Technology | Technology |
52-Week High | $202.09 | $150.42 |
52-Week Low | $108.27 | $61.99 |
Enterprise Value | $1.70T | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPCX stock trades at $147.99, up 6.67% today, with a bullish technical signal and strong analyst support. Recent news highlights AI growth and a $1.2 billion stake by Norway's sovereign wealth fund. However, the company shows negative net income margins and high valuation ratios, with revenue growth offset by profitability challenges.
The outlook is mixed: bullish sentiment and AI expansion offer upside, but high valuation and persistent losses pose risks. The consensus price target of $228.52 suggests potential growth, yet investors must weigh innovation against financial sustainability.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
